FY2025 EPS Estimates for Cingulate Cut by Zacks Small Cap

Cingulate Inc. (NASDAQ:CING) – Research analysts at Zacks Small Cap dropped their FY2025 earnings per share estimates for shares of Cingulate in a research note issued to investors on Monday, November 17th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings of ($3.65) per share for the year, down from their prior estimate of ($2.91). The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share. Zacks Small Cap also issued estimates for Cingulate’s Q4 2025 earnings at ($0.38) EPS, FY2026 earnings at ($0.95) EPS and FY2027 earnings at ($0.04) EPS.

Cingulate (NASDAQ:CING) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.55).

Several other equities research analysts have also recently weighed in on the stock. Roth Capital dropped their price target on shares of Cingulate from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cingulate in a research note on Wednesday, October 8th. Finally, Ascendiant Capital Markets raised their target price on Cingulate from $61.00 to $62.00 and gave the stock a “buy” rating in a research note on Friday, August 22nd. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $27.50.

Cingulate Stock Performance

Shares of Cingulate stock opened at $3.42 on Thursday. Cingulate has a 52-week low of $3.20 and a 52-week high of $6.01. The company’s 50 day moving average price is $3.80 and its 200-day moving average price is $4.12. The stock has a market capitalization of $23.11 million, a price-to-earnings ratio of -0.94 and a beta of -0.74.

Hedge Funds Weigh In On Cingulate

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quantum Private Wealth LLC grew its holdings in Cingulate by 140.0% during the 3rd quarter. Quantum Private Wealth LLC now owns 24,000 shares of the company’s stock valued at $94,000 after buying an additional 14,000 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Cingulate during the 2nd quarter worth approximately $45,000. Finally, Bank of America Corp DE boosted its position in shares of Cingulate by 283.1% during the 2nd quarter. Bank of America Corp DE now owns 7,501 shares of the company’s stock valued at $31,000 after acquiring an additional 5,543 shares during the last quarter. 41.31% of the stock is owned by institutional investors.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.